Dosimetric Impact of 4D-CT Ventilation Imaging-Based Functional Treatment Planning for Stereotactic Body Radiation Therapy

Abstract

1.022-1.057, p < 0.001) and locoregional control (HR Z 1.036 per 10 cc increase, 95% CI Z 1.012-1.061, p Z 0.004), while SUVmax was not prognostic. In a multivariable model that included clinical data and metrics from both preand post-treatment PET, both pre-treatment MTV (HR Z 1.032 per 10 cc increase, 95% CI Z 1.002-1.062, p Z 0.033) and posttreatment SUVmax (HR Z 1.131 per unit increase, 95% CI Z 1.059 to 1.207, p < 0.001) were independent predictors of overall survival. Posttreatment SUVmax was the only significant predictor of locoregional control. Conclusions: Pre-treatment tumor burden (MTV) measured on PET is a strong predictor of clinical outcomes for NSCLC patients treated with chemoradiation therapy and may serve as a valuable stratification factor in clinical trials for this patient population. Acknowledgment: This project has been funded at least in part with Federal funds from the Department of Health and Human Services under Grant Number CA80098. Author Disclosure: N. Ohri: None. F. Duan: None. M. Machtay: None. J.J. Gorelick: None. B.S. Snyder: None. A. Alavi: None. B. Siegel: None. D.W. Johnson: None. J.D. Bradley: None. A.S. DeNittis: None. M. Werner-Wasik: None.